Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment

被引：2
|
作者：
Serrati, Simona [1 ]
Margheri, Francesca [2 ]
机构：
[1] IRCCS Ist Tumori Giovanni Paolo II, Lab Expt Pharmacol, I-70124 Bari, Italy
[2] Univ Florence, Dept Expt & Clin Biomed Sci, I-50134 Florence, Italy
来源：
BIOMOLECULES | 2023年 / 13卷 / 08期
关键词：
IMMUNE; RESISTANCE;
D O I：
10.3390/biom13081209
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] PD-1 and PD-L1 antibodies in cancer: current status and future directions
    Arjun Vasant Balar
    Jeffrey S. Weber
    Cancer Immunology, Immunotherapy, 2017, 66 : 551 - 564
  • [22] Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions
    Liu, Zaoqu
    Han, Yilin
    Dang, Qin
    Xu, Hui
    Zhang, Yuyuan
    Duo, Mengjie
    Lv, Jinxiang
    Li, Huanyun
    Kong, Ying
    Han, Xinwei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 111
  • [23] Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
    Hongshu Li
    Ying Chang
    Tiefeng Jin
    Meihua Zhang
    Cancer Cell International, 25 (1)
  • [24] Antagonists of PD-1 and PD-L1 in Cancer Treatment
    Lipson, Evan J.
    Forde, Patrick M.
    Hammers, Hans-Berg
    Emens, Leisha A.
    Taube, Janis M.
    Topalian, Suzanne L.
    SEMINARS IN ONCOLOGY, 2015, 42 (04) : 587 - 600
  • [25] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hayashi, Hidetoshi
    Nakagawa, Kazuhiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 818 - 830
  • [26] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hidetoshi Hayashi
    Kazuhiko Nakagawa
    International Journal of Clinical Oncology, 2020, 25 : 818 - 830
  • [27] Correction to: Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors
    Sadal Refae
    Jocelyn Gal
    Nathalie Ebran
    Josiane Otto
    Delphine Borchiellini
    Frederic Peyrade
    Emmanuel Chamorey
    Patrick Brest
    Gérard Milano
    Esma Saada-Bouzid
    Investigational New Drugs, 2021, 39 : 287 - 292
  • [28] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Li, Qian
    Han, Jingjing
    Yang, Yonglin
    Chen, Yu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [29] Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (02) : 131 - 133
  • [30] Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors
    Zhao, S.
    Li, X.
    Wang, S.
    Wang, Y.
    Huang, D.
    Da, Y.
    Song, Z.
    Chen, J.
    Manegold, C.
    Peng, L.
    Xu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S651 - S651
12345